At the forefront of research into prevention of scar tissue formation after a heart attack

HEMEX is a proud partner of the European Consortium, that was awarded €4.5 million by the European Union for the ELR-SCAR project to validate a novel hydrogel biomaterial for prevention of scar tissue forming in the heart following a heart attack. This project will transform and fundamentally improve clinical practice in this crucial field of cardiology, resulting in a reduction of the enormous burden that MI and its leading cause, IHD, places on society as a whole and on the individual patient.

More info @University of Galway



HEMEX is committed to changing the future of healthcare by guiding the most promising European startups through each and every step to bring innovative pharmaceuticals, medical devices, and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure startups have access to a wide range of tailored products, practical solutions, and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare. For more information, visit